Clinical Trials

It would be an exaggeration to say that CBD is literally everywhere, but not much. Widely hailed as a miracle cure-oil, it’s been evangelically embraced by young and old, yoga bunnies and gym rats, hipsters and hippies – not to mention opportunistic marketers with a liberal attitude to scientific proof, if not false advertising. As […]

by

Both Strongbridge Biopharma plc (NASDAQ:SBBP) and Intec Pharma Ltd. (NASDAQ:NTEC) are each other’s competitor in the Biotechnology industry. Thus the compare of their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. Valuation and Earnings Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Strongbridge Biopharma plc and Intec Pharma […]

by

– Topline Data from BRIGHT Study Expected in the First Half 2020 – – Company Selects Zygel™ as Brand Name for ZYN002 CBD Transdermal Gel – DEVON, Pa., March 07, 2019 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that […]

by

As Biotechnology businesses, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Intec Pharma Ltd. (NASDAQ:NTEC), are affected by compare. This especially applies to their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership. Earnings and Valuation Table 1 highlights BioMarin Pharmaceutical Inc. and Intec Pharma Ltd.’s gross revenue, earnings per share (EPS) and valuation. Profitability Table 2 […]

by

As Biotechnology companies, INSYS Therapeutics Inc. (NASDAQ:INSY) and uniQure N.V. (NASDAQ:QURE) are our subject to contrast. And more specifically their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership. Valuation and Earnings Demonstrates INSYS Therapeutics Inc. and uniQure N.V. earnings per share (EPS), top-line revenue and valuation. Profitability Table 2 shows us the return […]

by

We will be contrasting the differences between XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) and Intec Pharma Ltd. (NASDAQ:NTEC) as far as analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry. Valuation and Earnings Table 1 highlights XTL Biopharmaceuticals Ltd. and Intec Pharma Ltd.’s gross revenue, […]

by

Intec Pharma Ltd. (NASDAQ:NTEC) and Matinas BioPharma Holdings Inc. (NYSEAMERICAN:MTNB) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation. Valuation and Earnings Demonstrates Intec Pharma Ltd. and Matinas BioPharma Holdings Inc. earnings per share, top-line revenue and […]

by

Since Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Intec Pharma Ltd. (NASDAQ:NTEC) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation of both companies. Earnings and Valuation Demonstrates Brainstorm Cell Therapeutics Inc. and Intec Pharma Ltd. earnings per share, […]

by

This is a contrast between INSYS Therapeutics Inc. (NASDAQ:INSY) and Otonomy Inc. (NASDAQ:OTIC) based on their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. The two companies are Biotechnology and they also compete with each other. Earnings and Valuation Table 1 highlights INSYS Therapeutics Inc. and Otonomy Inc.’s top-line revenue, earnings per share […]

by

MorphoSys AG (NASDAQ:MOR) and INSYS Therapeutics Inc. (NASDAQ:INSY), both competing one another are Biotechnology companies. We will compare their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation. Valuation Earnings In table 1 we can see MorphoSys AG and INSYS Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation. Profitability Table 2 shows […]

by

Both Intec Pharma Ltd. (NASDAQ:NTEC) and Tiziana Life Sciences PLC (NASDAQ:TLSA) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation. Earnings Valuation In table 1 we can see Intec Pharma Ltd. and Tiziana Life Sciences PLC’s […]

by

Marsico Capital Management Llc decreased its stake in Gw Pharmaceuticals Plc (GWPH) by 19.49% based on its latest 2018Q4 regulatory filing with the SEC. Marsico Capital Management Llc sold 17,968 shares as the company’s stock rose 45.17% with the market. The institutional investor held 74,219 shares of the major pharmaceuticals company at the end of […]

by

Since Reata Pharmaceuticals Inc. (NASDAQ:RETA) and Intec Pharma Ltd. (NASDAQ:NTEC) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation of both companies. Valuation Earnings In table 1 we can see Reata Pharmaceuticals Inc. and Intec Pharma Ltd.’s top-line […]

by

Intec Pharma Ltd. (NASDAQ:NTEC) and Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. Valuation Earnings Table 1 showcases the top-line revenue, earnings per share and valuation of […]

by